Crinetics Pharmaceuticals gains FDA approval for PALSONIFY, targeting key unmet needs in Acromegaly. Click here to read my ...

The Food and Drug Administration (FDA) has approved Palsonify ™ (paltusotine) for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an ...

Navratri fasting, a blend of devotion and discipline, sees millions abstaining from food for nine days. While short fasts ...

Crinetics’ PALSONIFY wins FDA approval as a new oral treatment for acromegaly, offering rapid, effective symptom control.

Paltusotine (Palsonify; Crinetics), a novel nonpeptide somatostatin receptor type 2 nonpeptide (SST2) agonist, was approved by the FDA for the treatment of acromegaly in adults who had an inadequate ...

The U.S. Food and Drug Administration approved Crinetics Pharmaceuticals' drug to treat a rare hormonal disorder on Thursday, ...

A major US study challenges common beliefs about protein and health. It found that animal protein consumption doesn't raise the risk of overall or hea ...

PALSONIFY™ (paltusotine) INDICATION: PALSONIFY is a somatostatin receptor agonist indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom ...

Crinetics Pharmaceuticals celebrates FDA approval of Palsonify, the first oral treatment for acromegaly, enhancing patient ...

The Member of Parliament for North Tongu, Samuel Okudzeto Ablakwa, in October 2024, exposed a US$38.2 million visa processing ...

Hair loss can be frustrating and, at times, alarming for both men and women. While genetics, stress, and hormones play major ...

The regulatory greenlight was backed by two Phase III trials that showed normalized growth hormone levels in patients with ...